TY - JOUR AU - Echeverría, N. AU - Moratorio, G. AU - Cristina, J. AU - Moreno, P. PY - 2015 DA - 2015// TI - Hepatitis C virus genetic variability and evolution JO - World J Hepatol VL - 7 UR - https://doi.org/10.4254/wjh.v7.i6.831 DO - 10.4254/wjh.v7.i6.831 ID - Echeverría2015 ER - TY - JOUR AU - Zeuzem, S. AU - Feinman, S. V. AU - Rasenack, J. AU - Heathcote, E. J. AU - Lai, M. Y. AU - Gane, E. PY - 2000 DA - 2000// TI - Peginterferon alfa-2a in patients with chronic hepatitis C JO - N Engl J Med VL - 343 UR - https://doi.org/10.1056/NEJM200012073432301 DO - 10.1056/NEJM200012073432301 ID - Zeuzem2000 ER - TY - JOUR AU - Heathcote, E. J. AU - Shiffman, M. L. AU - WGE, C. AU - Dusheiko, G. M. AU - Lee, S. S. AU - Balart, L. PY - 2000 DA - 2000// TI - Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis JO - N Engl J Med VL - 343 UR - https://doi.org/10.1056/NEJM200012073432302 DO - 10.1056/NEJM200012073432302 ID - Heathcote2000 ER - TY - JOUR AU - Trepo, C. AU - Habersetzer, F. AU - Bailly, F. AU - Berby, F. AU - Pichoud, C. AU - Berthillon, P. PY - 1994 DA - 1994// TI - Interferon therapy for hepatitis C JO - Antivir Res VL - 24 UR - https://doi.org/10.1016/0166-3542(94)90064-7 DO - 10.1016/0166-3542(94)90064-7 ID - Trepo1994 ER - TY - JOUR AU - Akram, M. AU - Idrees, M. AU - Zafar, S. AU - Hussain, A. AU - Butt, S. AU - Afzal, S. PY - 2011 DA - 2011// TI - Effects of host and virus related factors on interferon-α+ ribavirin and pegylated-interferon+ ribavirin treatment outcomes in chronic hepatitis C patients JO - Virol J VL - 8 UR - https://doi.org/10.1186/1743-422X-8-234 DO - 10.1186/1743-422X-8-234 ID - Akram2011 ER - TY - JOUR AU - Inamullah, I. AU - Idrees, M. AU - Ahmed, H. AU - Ali, M. AU - Ali, L. AU - Ahmed, A. PY - 2011 DA - 2011// TI - Hepatitis C virus genotypes circulating in district swat of Khyber Pakhtoonkhaw JO - Pakistan Virol J VL - 8 UR - https://doi.org/10.1186/1743-422X-8-16 DO - 10.1186/1743-422X-8-16 ID - Inamullah2011 ER - TY - JOUR AU - Rehman, I. -. u. AU - Idrees, M. AU - Ali, M. AU - Ali, L. AU - Butt, S. AU - Hussain, A. PY - 2011 DA - 2011// TI - Hepatitis C virus genotype 3a with phylogenetically distinct origin is circulating in Pakistan JO - Genet Vaccines Ther VL - 9 UR - https://doi.org/10.1186/1479-0556-9-2 DO - 10.1186/1479-0556-9-2 ID - Rehman2011 ER - TY - JOUR AU - Dusheiko, G. AU - Main, J. AU - Thomas, H. PY - 1996 DA - 1996// TI - Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study JO - J Hepatol VL - 25 UR - https://doi.org/10.1016/S0168-8278(96)80225-X DO - 10.1016/S0168-8278(96)80225-X ID - Dusheiko1996 ER - TY - JOUR AU - Idrees, M. PY - 2008 DA - 2008// TI - Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan JO - J Virol Methods VL - 150 UR - https://doi.org/10.1016/j.jviromet.2008.03.001 DO - 10.1016/j.jviromet.2008.03.001 ID - Idrees2008 ER - TY - JOUR AU - Shiffman, M. L. AU - Suter, F. AU - Bacon, B. R. AU - Nelson, D. AU - Harley, H. AU - Solá, R. PY - 2007 DA - 2007// TI - Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMoa066403 DO - 10.1056/NEJMoa066403 ID - Shiffman2007 ER - TY - JOUR AU - Alberti, A. PY - 2004 DA - 2004// TI - Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed? JO - J Hepatol VL - 40 UR - https://doi.org/10.1016/j.jhep.2004.04.008 DO - 10.1016/j.jhep.2004.04.008 ID - Alberti2004 ER - TY - JOUR AU - Marcellin, P. AU - Cheinquer, H. AU - Curescu, M. AU - Dusheiko, G. M. AU - Ferenci, P. AU - Horban, A. PY - 2012 DA - 2012// TI - High sustained virologic response rates in rapid virologic response patients in the large real world prophesys cohort confirm results from randomized clinical trials JO - Hepatology VL - 56 UR - https://doi.org/10.1002/hep.25892 DO - 10.1002/hep.25892 ID - Marcellin2012 ER - TY - JOUR AU - Lawitz, E. AU - Sulkowski, M. S. AU - Ghalib, R. AU - Rodriguez-Torres, M. AU - Younossi, Z. M. AU - Corregidor, A. PY - 2014 DA - 2014// TI - Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)61036-9 DO - 10.1016/S0140-6736(14)61036-9 ID - Lawitz2014 ER - TY - JOUR AU - Lawitz, E. AU - Gane, E. J. PY - 2013 DA - 2013// TI - Sofosbuvir for previously untreated chronic hepatitis C infection JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMc1307641 DO - 10.1056/NEJMc1307641 ID - Lawitz2013 ER - TY - JOUR AU - Kowdley, K. V. AU - Lawitz, E. AU - Crespo, I. AU - Hassanein, T. AU - Davis, M. N. AU - DeMicco, M. PY - 2013 DA - 2013// TI - Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial JO - Lancet VL - 381 UR - https://doi.org/10.1016/S0140-6736(13)60247-0 DO - 10.1016/S0140-6736(13)60247-0 ID - Kowdley2013 ER - TY - JOUR AU - Lawitz, E. AU - Lalezari, J. P. AU - Hassanein, T. AU - Kowdley, K. V. AU - Poordad, F. F. AU - Sheikh, A. M. PY - 2013 DA - 2013// TI - Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial JO - Lancet Infect Dis VL - 13 UR - https://doi.org/10.1016/S1473-3099(13)70033-1 DO - 10.1016/S1473-3099(13)70033-1 ID - Lawitz2013 ER - TY - JOUR AU - Akhter, T. S. AU - Umar, M. AU - Aslam, F. AU - Nisar, G. AU - Naseer, A. AU - Ahmad, S. PY - 2017 DA - 2017// TI - Sofosbuvir for the treatment of hepatitis c genotype 3 infected patients in pakistan JO - J Ayub Med Coll Abbottabad VL - 28 ID - Akhter2017 ER - TY - STD TI - Mansoor VB, Ahmed U, Jahanzaib M, Ali Z, Haroon MA, Ahmed H, et al. End treatment response in chronic hepatitis C patients to Sofosbuvir and Ribavirin. Ann of PIMS. 2016;127:127–30. ID - ref18 ER - TY - JOUR AU - Yang, M. AU - Rao, H. Y. AU - Feng, B. AU - Zhang, W. AU - Wei, L. PY - 2013 DA - 2013// TI - Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection: a meta analysis JO - J Gastroenterol Hepatol VL - 28 UR - https://doi.org/10.1111/jgh.12233 DO - 10.1111/jgh.12233 ID - Yang2013 ER - TY - JOUR AU - Aziz, H. AU - Raza, A. AU - Irfan, J. PY - 2016 DA - 2016// TI - Optimum predictors of therapeutic outcome in HCV patients in Pakistan JO - J Med Virol VL - 88 UR - https://doi.org/10.1002/jmv.24305 DO - 10.1002/jmv.24305 ID - Aziz2016 ER - TY - JOUR AU - Raza, A. AU - Ali, Z. AU - Irfan, J. AU - Murtaza, S. AU - Shakeel, S. PY - 2012 DA - 2012// TI - Analytical variables influencing the HCV RNA determination by TaqMan real-time PCR in routine clinical laboratory practice JO - Mol Biol Rep VL - 39 UR - https://doi.org/10.1007/s11033-012-1574-3 DO - 10.1007/s11033-012-1574-3 ID - Raza2012 ER - TY - JOUR AU - Aziz, H. AU - Raza, A. AU - Murtaza, S. AU - Waheed, Y. AU - Khalid, A. AU - Irfan, J. PY - 2013 DA - 2013// TI - Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Punjab Province in Pakistan and a phylogenetic analysis JO - Int J Infect Dis VL - 17 UR - https://doi.org/10.1016/j.ijid.2012.09.017 DO - 10.1016/j.ijid.2012.09.017 ID - Aziz2013 ER - TY - JOUR AU - Moreira, S. AU - Garcia, R. F. AU - Gutberlet, A. AU - Bertol, B. C. AU - Ferreira, L. E. AU - Pinho, M. D. PY - 2012 DA - 2012// TI - A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome JO - J Virol Methods VL - 184 UR - https://doi.org/10.1016/j.jviromet.2012.05.024 DO - 10.1016/j.jviromet.2012.05.024 ID - Moreira2012 ER - TY - JOUR AU - Aziz, H. AU - Raza, A. AU - Ali, K. AU - JZK, K. AU - Irfan, J. AU - Gill, M. L. PY - 2015 DA - 2015// TI - Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy JO - Int J Infect Dis VL - 30 UR - https://doi.org/10.1016/j.ijid.2014.09.021 DO - 10.1016/j.ijid.2014.09.021 ID - Aziz2015 ER - TY - JOUR AU - Ali, M. AU - Rehman, I. U. AU - Idrees, M. PY - 2014 DA - 2014// TI - Emergence of genetically variant hepatitis C virus population in response to increased antiviral drug pressure, Pakistan JO - Virus Genes VL - 48 UR - https://doi.org/10.1007/s11262-014-1047-y DO - 10.1007/s11262-014-1047-y ID - Ali2014 ER - TY - JOUR AU - Kumar, S. AU - Stecher, G. AU - Tamura, K. PY - 2016 DA - 2016// TI - MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets JO - Mol Biol Evol VL - 33 UR - https://doi.org/10.1093/molbev/msw054 DO - 10.1093/molbev/msw054 ID - Kumar2016 ER - TY - JOUR AU - Saitou, N. AU - Nei, M. PY - 1987 DA - 1987// TI - The neighbor-joining method: a new method for reconstructing phylogenetic trees JO - Mol Biol Evol VL - 4 ID - Saitou1987 ER - TY - JOUR AU - Felsenstein, J. PY - 1985 DA - 1985// TI - Confidence limits on phylogenies: an approach using the bootstrap JO - Evolution VL - 39 UR - https://doi.org/10.1111/j.1558-5646.1985.tb00420.x DO - 10.1111/j.1558-5646.1985.tb00420.x ID - Felsenstein1985 ER - TY - STD TI - Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Akuta N, et al. The impact of IL28B polymorphism and HCV NS5A resistance associated variants on treatment response with ledipasvir and sofosbuvir regimen in Japanese real-life settings. Hepatology. 2016;64(Suppl S1):968A–9A. https://liverlearning.aasld.org/aasld/2016/thelivermeeting/144845/hitomi.sezaki.the.impact.of.il28b.polymorphism.and.hcv.ns5a.resistance.html. UR - https://liverlearning.aasld.org/aasld/2016/thelivermeeting/144845/hitomi.sezaki.the.impact.of.il28b.polymorphism.and.hcv.ns5a.resistance.html ID - ref29 ER - TY - JOUR AU - Muir, A. J. AU - Gong, L. AU - Johnson, S. G. AU - Lee, M. M. AU - Williams, M. S. AU - Klein, T. E. PY - 2014 DA - 2014// TI - Clinical Pharmacogenetics implementation consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon- α–based regimens JO - Clin Pharmacol Ther VL - 95 UR - https://doi.org/10.1038/clpt.2013.203 DO - 10.1038/clpt.2013.203 ID - Muir2014 ER - TY - JOUR AU - Ali, M. AU - Afzal, S. AU - Zia, A. AU - Hassan, A. AU - Khalil, A. T. AU - Ovais, M. PY - 2016 DA - 2016// TI - A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges JO - Medicine (Baltimore) VL - 95 UR - https://doi.org/10.1097/MD.0000000000005327 DO - 10.1097/MD.0000000000005327 ID - Ali2016 ER - TY - JOUR AU - Lawitz, E. AU - Mangia, A. AU - Wyles, D. AU - Rodriguez-Torres, M. AU - Hassanein, T. AU - Gordon, S. C. PY - 2013 DA - 2013// TI - Sofosbuvir for previously untreated chronic hepatitis C infection JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1214853 DO - 10.1056/NEJMoa1214853 ID - Lawitz2013 ER - TY - JOUR AU - Poordad, F. AU - Bronowicki, J. P. AU - Gordon, S. C. AU - Zeuzem, S. AU - Jacobson, I. M. AU - Sulkowski, M. S. PY - 2012 DA - 2012// TI - Factors that predict response of patients with hepatitis C virus infection to boceprevir JO - Gastroenterology VL - 143 UR - https://doi.org/10.1053/j.gastro.2012.05.011 DO - 10.1053/j.gastro.2012.05.011 ID - Poordad2012 ER - TY - JOUR AU - Alghamdi, A. S. AU - Alqutub, A. AU - Abaalkhail, F. AU - Sanai, F. M. AU - Alghamdi, H. AU - Altraif, I. PY - 2015 DA - 2015// TI - SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection JO - Saudi J Gastroenterol VL - 21 UR - https://doi.org/10.4103/1319-3767.153810 DO - 10.4103/1319-3767.153810 ID - Alghamdi2015 ER - TY - JOUR AU - Charlton, M. AU - Gane, E. AU - Manns, M. P. AU - Brown, R. S. AU - Curry, M. P. AU - Kwo, P. Y. PY - 2015 DA - 2015// TI - Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation JO - Gastroenterology VL - 148 UR - https://doi.org/10.1053/j.gastro.2014.10.001 DO - 10.1053/j.gastro.2014.10.001 ID - Charlton2015 ER - TY - JOUR AU - Costantino, A. AU - Spada, E. AU - Equestre, M. AU - Bruni, R. AU - Tritarelli, E. AU - Coppola, N. PY - 2015 DA - 2015// TI - Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C JO - Virol J VL - 12 UR - https://doi.org/10.1186/s12985-015-0414-1 DO - 10.1186/s12985-015-0414-1 ID - Costantino2015 ER - TY - JOUR AU - Donaldson, E. F. AU - Harrington, P. R. AU - O'Rear, J. J. AU - Naeger, L. K. PY - 2015 DA - 2015// TI - Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir JO - Hepatology VL - 61 UR - https://doi.org/10.1002/hep.27375 DO - 10.1002/hep.27375 ID - Donaldson2015 ER -